View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBod Science 将来の成長Future 基準チェック /06現在、 Bod Scienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長49.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Aug 25Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022Bod Australia Limited provided revenue guidance for the fiscal year 2022. The Company expects that revenue will continue to increase during FY2022, driven by recurring sales orders for CBD wellness products, an ongoing upward trajectory in medicinal cannabis sales, range expansions across both operating divisions and international expansion opportunities.すべての更新を表示Recent updatesお知らせ • Nov 10Bod Science Limited announced that it expects to receive AUD 2.05 million in fundingBod Science Limited announced a private placement of 68,333,333 fully paid ordinary shares at an issue price of AUD 0.03 per share for the gross proceeds of AUD 2,049,999.99 on November 8, 2023. The company will raise the funding in two tranches. The company will issue of 26,600,000 shares for the gross proceeds of AUD 80,000 in the first tranche and 41,700,000 shares for the gross proceeds of AUD 1,250,000 in second tranche. Tranche 2 includes the proposed issue of AUD 30,000 worth of shares to Jo Patterson subject to shareholder approval. Assuming Tranche 2 is approved, the transaction will involve the issue of 68.3 million shares. The transaction will include participation from new investor Antah Healthcare Group through a commitment of AUD 1,100,000 worth of shares. On completion of the transaction, it is expected that Antah Healthcare Group will hold a relevant interest of 14.9% of company's issued shares.お知らせ • Nov 09Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,600,773 Price\Range: AUD 0.03 Security Name: Shares Security Type: Common Stock Securities Offered: 41,732,556 Price\Range: AUD 0.03 Transaction Features: Subsequent Direct Listingお知らせ • Oct 07Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 19,751,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,875,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 02Bod Science Limited, Annual General Meeting, Nov 27, 2023Bod Science Limited, Annual General Meeting, Nov 27, 2023. Agenda: To consider and approve the re-election of Directors.Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)Full year 2023 results: AU$0.056 loss per share (further deteriorated from AU$0.051 loss in FY 2022). Revenue: AU$3.64m (down 28% from FY 2022). Net loss: AU$7.95m (loss widened 47% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.New Risk • Aug 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (AU$14.0m market cap, or US$9.00m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$4.1m revenue, or US$2.6m).New Risk • Aug 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Market cap is less than US$10m (AU$12.8m market cap, or US$8.31m). Minor Risk Revenue is less than US$5m (AU$4.1m revenue, or US$2.7m).お知らせ • Aug 11Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.Bod Australia Limited (ASX:BOD) entered into binding agreement to acquire Aqua Phase Ltd for £3 million on August 30, 2022. Bod will pay total consideration of £3 million with Initial payment of £1 million in cash to be paid upon satisfaction of conditions precedent relating to successful completion of upcoming manufacture, stability and bioavailability testing. Remaining consideration paid against further milestone achievements relating to pharmaceutical GMP manufacture and commercialization, with optionality for Bod to pay in cash or shares over a 12-36 month timeframe. The earnout payments are conditional upon ASX and shareholder's approval. As on March 7, 2023, Bod has successfully completed the stability testing of the Aqua Phase product format within the agreed time frame, along with the manufacture of a technical batch per the acquisition terms and timeframe. Due to third party delays involved in the testing and analyzing phase of the PK study, Bod Science has agreed with the Inventors to extend the date by which this test must be completed to June 30, 2023. As on March 28, 2023, Bod Science is pleased to report the PK study to confirm the bioavailability of Aqua Phase has been submitted for ethics approval, with approval expected within 2 weeks. Recruitment for study participants will commence immediately once ethics approval is received. The PK study will recruit 12 subjects and will continue for 4 weeks. Results are expected in June 2023. Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd on August 10, 2023.Reported Earnings • Feb 25First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)First half 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.02 loss in 1H 2022). Revenue: AU$2.57m (down 25% from 1H 2022). Net loss: AU$3.17m (loss widened 46% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.お知らせ • Jan 24Bod Science Limited Announces Company Secretary ChangesBod Science Limited announced the appointment of Carlie Hodges as Company Secretary upon the resignation of Stephen Kelly, effective 23 January 2023. Carlie is a practising corporate and commercial lawyer, holds a Graduate Diploma in Applied Corporate Governance and is a Fellow Member of the Governance Institute of Australia.お知らせ • Nov 22Bod Australia Limited Provides Statistical Summary from Its Phase 1 Cannabidiol (CBD) Pharmacokinetic (PK) StudyBod Australia Limited provide the following statistical summary from its Phase 1 cannabidiol (CBD) pharmacokinetic (PK) study. The PK study, undertaken as part of a number of elements within Bod's Schedule 3 (pharmacist only) project, forms a critical and required step for the Company's dossier submission to the TGA (Therapeutic Goods Association). Bod's ongoing Phase IIb clinical trial underpins the Company's drive to develop a new Schedule 3 (pharmacist only) CBD product to be made available to the Australian market. This supports Bod's strategy of consistently selling products through SAS-B channels since 2018 which has allowed the Company to build a strong foothold in the market. The PK study consisted of 3 oral treatment arms delivered as a single dose in a crossover design in 14 healthy subjects between 18-50 years old, each equating to 100mg CBD per day: Bod ECS BioAbsorb Soft Gel Capsule; Epidyolex Oil (a TGA & FDA-approved, plant-derived, purified prescription cannabidiol); CBD isolate in MCT oil (a supplement made from a structure of fat termed medium-chain triglycerides). Statistical analysis received on the study supports the potential for Bod's unique ECS BioAbsorb Soft Gel to be the benchmark delivery format for the over the counter CBD market. The below outcomes were reported in relation to the trial's primary and secondary endpoints: Bod ECS BioAbsorb Softgel showed over 20% greater concentration of CBD in the blood than Epidyolex; Bod ECS BioAbsorb Softgel showed over 400% greater concentration of CBD in the blood than CBD Isolate Oil solution; The maximum concentration of CBD after a single oral administration of Bod ECS BioAbsorb Softgel was over 60% greater than Epidyolex; The maximum concentration of CBD after a single oral administration of Bod ECS BioAbsorb Softgel was 600% more than CBD Oil solution; The time to reach the maximum concentration of CBD after single oral administration of Bod ECS BioAbsorb Softgel was twice as fast as Epidyolex and five times faster than CBD Oil solution.Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Nov 09Bod Australia Limited Announces Resignation of Hanno Cappon as Non-Executive DirectorBod Australia Limited advised that Mr. Hanno Cappon has resigned as Non-Executive Director with immediate effect. Mr. Cappon joined the Company's Board in July 2021 as one of two Directors appointed by NewH2 and H&H pursuant to the investment agreement between the Company and NewH2 and H&H. Following the completion of the recent placement and entitlement offer, NewH2's shareholding in the Company has reduced to less than ten per cent of the Company's fully paid ordinary shares on issue and, in accordance with the investment agreement, the number of Directors appointed by NewH2 and H&H is to be reduced to a single Director. Mr. Akash Bedi will remain on the Board as the appointee of NewH2 and H&H. The Company continues to assess additional director candidates to ensure it has adequate diversity and the necessary skill sets to advance its current clinical trial pipeline and product commercialisation initiatives. The Company advises that following Mr. Cappon's resignation, Resolution 15 from the agenda of the Annual General Meeting of Shareholders scheduled for 4.00pm (AEDT) on 28 November 2022 has been withdrawn.お知らせ • Oct 18Bod Australia Limited, Annual General Meeting, Nov 28, 2022Bod Australia Limited, Annual General Meeting, Nov 28, 2022.Reported Earnings • Aug 31Full year 2022 earnings released: AU$0.051 loss per share (vs AU$0.043 loss in FY 2021)Full year 2022 results: AU$0.051 loss per share (down from AU$0.043 loss in FY 2021). Revenue: AU$5.28m (down 29% from FY 2021). Net loss: AU$5.41m (loss widened 28% from FY 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.お知らせ • Jun 23Bod Australia Limited to Launch a New Medicinal Cannabis Product to the Australian Market in JulyBod Australia Limited announced that it will launch a new medicinal cannabis product to the Australian market in July, available to consumers through the Therapeutic Goods Administration's (TGA) Special Access Scheme Category B.The TGA's Schedule Access Scheme allows certain healthcare practitioners to access certain therapeutic goods including medicines, medical devices and biologicals that are not included in the Australian Register of TherapeuticGoods (ARTG) for a single patient. Bod has been consistently selling products through SAS-B channels since 2018 and has built a strong foothold in the market. The new product will be launched under Bod's existing medicinal cannabis brand as MediCabilisTM and sold as Bod Bio-Absorb 100TM. Bio-Absorb 100TM is made up of a uniquely developed CBD formulation in a soft gel delivery format and is currently being utilised in the Company's phase II clinical trial. The launch will highlight the Company's fourth product available to Australian consumers through prescription channels. Upon successful completion of Bod's phase II clinical trial and other required regulatory approvals, Bio-Absorb 100TM will be sold over-the-counter through pharmacists. The launch of Bod Bio-Absorb 100TM will expand Bod's existing medicinal cannabis range, introduce a new delivery format for consumers and complement the Company's existing products that are being used to alleviate a range of conditions including chronic pain, anxiety and insomnia amongst others. To drive product awareness and uptake, the Company has engaged with a number of healthcare professionals and approved prescribers to further educate them on the benefits of Bod Bio-Absorb 100TM. Bod will provide additional updates on the launch and product sales growth as it materialises.お知らせ • May 26Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising ResultsBod Australia Limited announced that it has completed a proof of concept study into the safety and efficacy of a cannabigerol (CBG) dominant cannabis extract which has shown very promising results. The study will form the basis for the launch of a new medicinal cannabis product that will be sold under Bod's existing medicinal cannabis brand as MediCabilisTM CBG 50, expected to launch in June 2022. CBG is a non-intoxicating cannabinoid compound, found in the cannabis plant. It holds strong therapeutic potential across a range of applications. Preliminary research has indicated that CBG has unique pharmacological actions and has the potential to address alternative therapeutic areas to THC and CBD. The extract has been shown to be beneficial in the treatment of fibromyalgia, inflammatory bowel disease and irritable bowel syndrome (IBS) amongst others. Treatment of these conditions commonly includes a mix medication, surgery and self-care strategies, with no single treatment procedure working on all symptomsi. Bod's proof of concept study was conducted over a three month period to assess the safety and efficacy of MediCabilisTM CBG 50 in patients suffering from symptoms associated with fibromyalgia, inflammatory bowel disease and anxiety. During the trial, participants were administered 50mg/ml of the product orally, twice daily and asked to rate the improvement in symptoms on a scale of one to ten, with one being nothing to ten being the best improvement. A comprehensive review of the data highlighted that 74% of trial participants reported a noticeable improvement in their conditions within two to four weeks of using MediCabilisTM CBG 50 twice a day. When participants were asked to rate the improvement on a scale of one to ten, 64% reported a rating above six. The detailed trial data will be shared with doctors and approved prescribers in both Australia and the UK to assist in the ongoing educational initiatives undertaken by the Company and to support the launch of MediCabilisTM CBG 50. The Company expects to launch MediCabilisTM CBG 50 in June 2022 via prescription channels. This will complement and expand Bod's existing medicinal cannabis product range, which is currently being used to alleviate a range of conditions including chronic pain, anxiety and insomnia amongst others. Bod will also become the first company to launch a pharmaceutical grade CBG product in the Australian and UK prescription market, providing another channel to grow medicinal cannabis sales.お知らせ • May 18Bod Australia Limited Announces Board ChangesBod Australia Limited advised that Mr. Mark Masterson has resigned as Non-Executive Chairman, effective from May 16, 2022 due to personal reasons. Recently appointed Non-Executive Director Mr. David Baker will now assume the role of Non-Executive Chairman. Mr. Baker joined the Company in April 2022. He is a commercial adviser and company director with over 40 years' experience in law, investment banking, public company leadership and corporate governance. Mr. Baker is also a longstanding shareholder in Bod.お知らせ • May 12Bod Australia Limited Advises That It Has Successfully Enrolled First Patients for Its Australian-Based Planned Phase Iib Clinical TrialBod Australia Limited advised that it has successfully enrolled first patients for its Australian-based planned Phase IIB clinical trial to investigate the efficacy of a new, unique Schedule 3(pharmacist only) CBD formulation on symptoms associated with insomnia. Bod's trial is a double blind, randomised and placebo-controlled investigation of the effect of administering a 50mgand 100mg oral CBD product per day, versus a placebo, over an 8-week period with over 200 participants. Upon completion of the study, Bod is confident that it will have sufficient data to progress product registration for Schedule 3 low dose CBD product with the Therapeutic Goods Administration (TGA) and for the final product to be added to the Australian Register of Therapeutic Goods (ARTG). Expected to be one of the first companies in Australia to do so, the completion of this process provides Bod with a unique CBD product that can be sold over-the-counter by a pharmacist to Australian consumers who are seeking to alleviate symptoms of insomnia, without the requirement of a prescription. With a potential market valued at$250m, the new product will unlock another channel for Bod to significantly increase domestic sales. Importantly, the clinical trial has the potential to unlock opportunities in the growing global insomnia market, which is expected to reach USD 6.38Bn in value by 2030.お知らせ • Apr 27Bod Australia Limited Announces First Patients Enrolled for Long-Covid Study Investigating the Efficacy of CBD- Dominant Medicinal CannabisBod Australia Limited announced that it has enrolled first patients for its UK-based open label clinical trial in collaboration with Drug Science UK to explore the effectiveness of Bod's medicinal cannabis product MediCabilis® CBD 5% (`MediCabilis') on associated with the long term impact of SARS-CoV-2 (`COVID-19'), which is commonly referred to as long-COVID. Long-COVID is an emerging condition referring to the ongoing or new symptoms that develop in the eight weeks following an initial COVID-19 infection. The condition may include the continuation of COVID-19 symptoms frominitial diagnosis, or new symptoms that arise around a month after contracting the disease. Symptoms of long-COVID include shortness of breath, fatigue, ongoing chest discomfort, loss of concentration, chronic pain, anxiety and insomnia. Many of these are amenable to treatment with cannabis-based medicines, highlighting Bod's significant near-term opportunity. The study aims to recruit 30 participants over the age of 18 that are suffering from long-COVID. Under a clinical trial setting, each patient will be administered MediCabilis on a daily basis over a six month period and undertake self- reporting assessing common long-COVID symptoms including breathlessness, fatigue, cognition and pain through a dedicated smartphone application. The collective results of the trial will determine the feasibility of Bod's medicinal cannabis product in the treatment of the condition and whether it is effective and safe to use for long COVID condition. The results from the clinical trial will allow Bod to continue the potential commercialization of a product which can alleviate symptoms of long-COVID, provide the Company with additional evidence in the use of MediCabilisand assist Bod in progressing potential Licensing agreements with large pharmaceutical partners or other corporates for its unique extract.Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Chairman Mark Masterson was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Apr 04Bod Australia Announces Board ChangesBod Australia Limited advised that Mr. Simon O'Loughlin has retired as a Non-Executive Director. Mr. O'Loughlin will be replaced by Mr. David Baker. Mr. Baker has been appointed as a Non-Executive Director effective 4 April 2022. Mr. Baker is a commercial advisor and company director with over 40 years' experience in law, investment banking, public company leadership and corporate governance. He has deep industry knowledge across a range of sectorsand a sophisticated understanding of financial markets.Reported Earnings • Feb 28First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.02 loss per share (down from AU$0.014 loss in 1H 2021). Revenue: AU$3.44m (up 4.0% from 1H 2021). Net loss: AU$2.17m (loss widened 68% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.お知らせ • Feb 21Bod Australia Limited's Novel Food Application Accepted by UK Food Service AgencyBod Australia Limited to advise that its submitted dossier to the United Kingdom's Food Service Agency to register its exclusive cannabis extract as a novel food in the UK has been validated - the final step in this process will be to receive the registration. The Company's dossier is currently under review by the regulator and final approval is expected in the coming months. Lodgement of the dossier follows changes by the FSA that required products containing CBD be subject to novel food standards. The deadline for submissions was March 2021, and approval will allow Bod's range of CBD products to continue to be sold in the UK legally. It will also provide the Company with the opportunity to pursue additional partnerships to introduce new products across a range of verticals. Bod has an established footprint in the UK and currently distributes both medicinal cannabis and CBD wellness products in the region. Bod's leading MediCabilis Medical Cannabis product is available through the special access market via prescription. Bod also sells 15 CBD wellness products through its, global partner, Health & Happiness Group Limited under brands CBII and Swisse. The pending approval reinforces the quality of the Company's CBD extract and provides Bod with a significant competitive advantage. It will also allow the Company to progress the introduction of new CBD-based, over the counter products in other high growth verticals including skincare, beverages and lifestyle products, functional food and pet treats. The Company is in discussions with a number of potential partners and will provide additional updates as developments materialise. Bod has undertaken a considerable amount of work to progress the registration with the FSA, including toxicology studies, stability testing and extract analysis initiatives. The data from these studies has also been used to advance European novel foods registration through EFSA. European novel foods registration is expected to unlock several additional opportunities, allowing Bod to broaden its global footprint.お知らせ • Jan 24Bod Australia Limited Announces Ethics Approval Received for Schedule 3 Clinical TrialBod Australia Limited advised that the company's planned phase IIB clinical trial to be undertaken at the Woolcock Institute of Medical Research has received ethics approval from Bellberry Limited. The trial will investigate the efficacy of a new unique Schedule 3 (pharmacist only) CBD formulation on symptoms associated with insomnia. This is a major milestone for the Company allowing the immediate commencement of participant recruitment for the study. The Woolcock Institute of Medical Research is Australia's leading sleep and respiratory research organisation. The trial will be a double blind, randomised and placebo-controlled investigation of the effect of administering a 50mg and 100mg oral CBD product per day, versus a placebo, over a 8-week period with over 200 participants. The clinical trial is one of the first registered in Australia for a Schedule 3 CBD product. Following completion of the study, Bod expects to have sufficient data to commence product registration for a Schedule 3 low dose CBD product with the Therapeutic Goods Administration (TGA) and for the product to be included on the Australian Register of Therapeutic Goods (ARTG). It is anticipated that completion of this process will provide Bod with a low dose CBD product that can be sold over-the-counter by a pharmacist to Australian consumers without a prescription. This unlocks another channel to market for the Company and has the potential to significantly increase domestic sales, underpinning additional revenue growth. Insomnia provides a large opportunity for Bod. In an estimated global market of $5.4 Billion by 2023, current pharmacological interventions for the treatment of insomnia have major limitations including abuse and dependence, questionable or uncertain efficacy and hangover effects. The successful development of Bod's product will provide it with a defined pathway to market and an opportunity to grow its market share. Ethics approval underpins Bod's strong momentum bringing its Schedule 3 products to market. Participant recruitment will commence shortly and Bod is also in advanced discussions with a number of potential partners for its Schedule 3 CBD products and expects to provide additional updates on these over the coming months.お知らせ • Jan 18Bod Australia Limited Announces Secures Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory AgencyBod Australia Limited announced that it has secured Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory Agency ("MHRA") to commence an open label clinical trial in association with Drug Science UK to explore the effectiveness of Bod's medicinal cannabis product, MediCabilis® 5% ("MediCabilis®") on symptoms associated with the long term impact of SARS-CoV-2 ("COVID-19"), commonly referred to as long-COVID. This initiative provides Bod with an important opportunity to build on the growing body of evidence for the use of MediCabilis®, as well as insight into the potential use of the product as a treatment against long-COVID. Upon completion of the trial and pending successful results, Bod will embark on the commercialisation of a MediCabilis® product which can be used to treat the condition. The Company anticipates that this will lead to increased sales volumes across the UK and other territories. Long-COVID is an emerging condition referring to persistent or new symptoms that develop at least eight weeks following an initial COVID-19 infection. Long-COVID may include the continuation of symptoms from when an individual is first infected, or new symptoms where individuals feel they have improved and a month after being infected symptoms arise again. Under the clinical trial setting, recruits will be administered Bod's medicinal cannabis product, MediCabilis®,on a daily basis, over a six-month period. Each participant will undertake monthly and daily self-reporting assessing common long-COVID symptoms such as breathlessness, fatigue, cognition and pain via a smartphone app. The collective results will determine the feasibility of medicinal cannabis and MediCabilis® in the treatment of the condition and whether it is safe to use.分析記事 • Sep 23Here's Why We're Watching Bod Australia's (ASX:BDA) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...お知らせ • Aug 25Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022Bod Australia Limited provided revenue guidance for the fiscal year 2022. The Company expects that revenue will continue to increase during FY2022, driven by recurring sales orders for CBD wellness products, an ongoing upward trajectory in medicinal cannabis sales, range expansions across both operating divisions and international expansion opportunities.Reported Earnings • Aug 24Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$7.53m (up 27% from FY 2020). Net loss: AU$4.23m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.お知らせ • Jun 17Bod Australia Limited Launches New CBD -Based ProductsBod Australia Limited announced that it has broadened its sales footprint in the United Kingdom via two new online retailers, following the launch of new CBD-based products sold under the CBII brand. The CBII range will now be stocked with Europe's number one online premium health and beauty retailer Lookfantastic, as well as Feelunique, one of Europe's leading premium ecommerce beauty retailers. Lookfantastic is one of the most successful beauty websites globally, stocking 660 premium brands and shipping to over 200 countries. Its UK website generates over 10 million visits per month. The group has grown revenue share 40% year on year for the last three yearsii and is underpinned by unrivalled technology, supply chain management and a team of world-class experts in the beauty and healthcare space. Initially, Lookfantastic will focus on the sale and distribution of CBII products in the UK, with both parties exploring the potential to expand availability to other countries where CBD is legally permissible for sale. CBII products will be launched on Lookfantastic's website in the coming weeks.分析記事 • Jun 07Bod Australia (ASX:BDA) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • May 18Bod Australia Limited Provides Update on New Medicinal Cannabis Product LaunchBod Australia Limited provided the update on a new medicinal cannabis product launch and recent MediCabilisTM prescription growth in the United Kingdom. The Company is launching a new cannabigerol (CBG) product, which will be sold under the MediCabilis brand as MediCabilisTM CBG 50 in the United Kingdom. CBG is a non-intoxicating cannabinoid compound in the cannabis plant, which holds strong therapeutic potential for use in broad therapeutic applications. Preliminary research indicates that CBG has unique pharmacological actions and has the potential to address alternative therapeutic areas to THC and CBD. CBG has a different chemical structure to CBD and THC and will bind onto specific cell receptors for different therapeutic targets. Bod is launching the product following R&D assessments, with the introduction as part of the Company's approach to developing specific cannabis cultivators and product formats for current and future new product development. The market for CBG is in its early stages and is expected to grow significantly in the coming years. The launch of MediCabilisTM CBG 50 will provide Bod with a first-mover advantage and leaves the Company very well placed to capitalise. Initially, Bod will focus on launching the product in the UK, through select doctors and healthcare physicians. The introduction of MediCabilisTM CBG 50 is expected to support incremental market growth across the region, as well and provide additional R&D and clinical research opportunities. Bod reported strong quarter on quarter MediCabilisTM prescription growth in the UK. During previous quarter, the Company filled a total of 59 MediCabilisTM units, which marks a 90% increase on the previous quarter. Bod expects that UK MediCabilisTM prescription volumes will continue an upward trajectory following the launch of the Company's new CBG product, Project Twenty21 scale up and ongoing educational initiatives to promote the company's products with approved prescribers in the UK market.Executive Departure • Apr 02Chief Financial Officer has left the companyOn the 29th of March, Charles Altshuler's tenure as Chief Financial Officer ended after 2.2 years in the role. We don't have any record of a personal shareholding under Charles' name. Charles is the only executive to leave the company over the last 12 months.分析記事 • Feb 22Why Bod Australia's (ASX:BDA) CEO Pay MattersThe CEO of Bod Australia Limited ( ASX:BDA ) is Jo Patterson, and this article examines the executive's compensation...お知らせ • Feb 19Bod Australia Limited Announces the Resignation of Charles Altshuler as Chief Financial Officer, Effective 31 March 2021Bod Australia Limited announced that Charles Altshuler has resigned from his position as Chief Financial Officer, effective 31 March 2021. Charles was appointed to the position in February 2019 and has assisted Bod in achieving a number of critical milestones. The Board of Bod Australia Limited wish him well for his future endeavours. The company will provide a further announcement upon the appointment of a new Chief Financial Officer when applicable.Is New 90 Day High Low • Feb 01New 90-day low: AU$0.42The company is down 14% from its price of AU$0.49 on 03 November 2020. The Australian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 1.0% over the same period.お知らせ • Dec 13Bod Australia Limited announced that it expects to receive AUD 8 million in fundingBod Australia Limited (ASX:BDA) announced a private placement of 14,545,455 common shares at a price of AUD 0.55 per share for gross proceeds of AUD 8,000,000.25 on December 11, 2020. The transaction will include participation from from institutional and sophisticated investors. The company expects to close the transaction on December 21, 2020.お知らせ • Dec 03Bod Australia Limited Receives AUD 200,000 Binding Purchase Order from Exclusive Global PartnerBod Australia Limited announced that it has received a AUD 200,000 binding purchase order from exclusive global partner, Health & Happiness Group Limited for four Swisse Wellness ('wisse') branded hemp seed oil products. The products will be sold in France, as well as through existing channels in the Netherlands and the United Kingdom, considerably broadening Bod's product offering in Europe. The products will be sold in soft gel cap form and designed to target specific need states including sleep, energy levels, stress and general wellness. The development marks Bod's entry into the French market. Bod and H&H will launch the products directly to consumers in France through Swisse's established ecommerce channels. Distribution to retail outlets is earmarked for future development. H&H will initiate marketing campaigns to progress product uptake and awareness in the country, as well as manage distribution. The new hemp seed oil products will also be sold through online channels in the United Kingdom, the Netherlands and Italy. Bod will receive a royalty on net product sales, as well as a cost plus margin for the supply of its extracts and formulas, unlocking more revenue streams. The binding purchase order follows a decision from the Court of Justice of the European Union ("CJEU") on 19 November 2020 which ruled that member states cannot prohibit the marketing of lawfully produced CBD. The CJEU ruled that CBD is not considered a narcotic and as a result, can be freely sold in the European Unionii.Is New 90 Day High Low • Nov 24New 90-day high: AU$0.61The company is up 110% from its price of AU$0.29 on 26 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 6.0% over the same period.お知らせ • Nov 18Bod Australia Limited Announces Strong Growth in Medicinal Cannabis Sales ContinuesBod Australia Limited announced that it has continued its strong medicinal cannabis sales growth filling 755 MediCabilis(TM) prescriptions during October 2020. This outlines a 106% increase on the average monthly prescription volumes since July 2019 (average monthly volumes: 371). October prescription volumes were part of the record purchase order received during first quarter of 2021 for 2,630 units, which following delivery, will now be booked as sales. Bod has now filled a total of 4,400 prescriptions since January 2020, which marks a 124% increase on 2019 volumes (2019 total prescription volumes: 1,959). The ongoing upward trajectory in prescription volumes has significantly added to the Company's revenue profile and demonstrates the traction that MediCabilis(TM) is gaining in the Australian market with a wide range of new and repeat patients. Repeat prescriptions for October accounted for 60% of the month's total volume. This highlights patient and physician satisfaction with the product, as well as the benefits MediCabilis(TM) is delivering to patients by alleviating chronic conditions. MediCabilis(TM) is being prescribed for a range of conditions and Bod now has a 57% market share in the addressable market defined by full plant, high CBD products in Australia. This is a major achievement given the highly competitive nature of the market. Bod anticipates that strong MediCabilis(TM) sales growth will continue over the coming months in Australia due to the increased brand recognition being achieved, and the Company's nationwide clinical observational study.お知らせ • Oct 20Bod Australia Limited Launches CBD Products in the NetherlandsBod Australia Limited advised that it has launched four new CBD products in the Netherlands, under recognised Australian vitamin and skincare brand Swisse Wellness ("Swisse"). The CBD products, which are in soft gel cap form and designed to target specific need states including immune function and joint mobility, are now being sold through Swisse's ecommerce channels and in store at established health food chain Holland and Barrett. A Swisse-branded marketing and sales campaign and in store promotions are supporting the launch. The launch follows Bod's exclusive global partnership with Swisse's parent company, Health and Happiness Group Limited and marks the third major market into which both parties have successfully launched products. Bod and H&H's products are now being sold in Australia, the United Kingdom and the Netherlands, with entry into additional European countries and the United States expected in coming months. As per the Company's exclusive licensing agreement with H&H, Bod will receive a royalty on net product sales as well as a cost plus margin for the supply of its CBD extract and formulas. Revenue from first Netherland sales is expected to fall in the current quarter as products are now available to consumers.お知らせ • Oct 15Bod Australia Limited Undertakes a Phase I Trial of the Safety Tolerability and Pharmacokinetics of Cannabidiol, Administered in Healthy Volunteers Across Multiple FormulationsBod Australia Limited has undertaken a Phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol (CBD), administered in healthy volunteers across multiple formulations, conducted at the Nucleus Network. The study, published in leading British Journal of Clinical Pharmacology, demonstrates the safety, tolerability and bioavailability of Cannabis sativa – Linnea 315CSE extract (available as MediCabilis(TM) Cannabis sativa 50) in oil and sublingual wafer formation compared to nabiximols oromucosal spray. About 43% of the adults in the UK have chronic pain, with as many as 14.3% having moderate to severely disabling chronic pain. Chronic pain is highly resistant to existing pharmaceutical treatment.Is New 90 Day High Low • Oct 15New 90-day high: AU$0.53The company is up 104% from its price of AU$0.26 on 17 July 2020. The Australian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 41% over the same period.Is New 90 Day High Low • Sep 28New 90-day high: AU$0.40The company is up 46% from its price of AU$0.27 on 30 June 2020. The Australian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 16% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Bod Science は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ASX:BOD - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20233-8-6-6N/A3/31/20234-7-5-5N/A12/31/20224-6-4-4N/A9/30/20225-6-4-4N/A6/30/20225-5-4-4N/A3/31/20226-5-5-5N/A12/31/20218-5-6-6N/A9/30/20218-5-6-6N/A6/30/20217-4-6-6N/A3/31/20217-4-5-5N/A12/31/20207-5-5-5N/A9/30/20207-5-4-4N/A6/30/20206-5-4-3N/A3/31/20204-6-5-4N/A12/31/20192-6-6-6N/A9/30/20192-7-6-6N/A6/30/20191-8-7-6N/A3/31/20191-6-6-5N/A12/31/20181-5-5-4N/A9/30/20181-4-4-4N/A6/30/20181-4-3-3N/A3/31/20181-3-3-3N/A12/31/20171-3-2-2N/A9/30/20171-3-2-2N/A6/30/20170-3-2-2N/A3/31/20170-3N/A-2N/A12/31/20160-2N/A-1N/A9/30/20160-1N/A-1N/A6/30/201600N/A0N/A6/30/201500N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BODの予測収益成長が 貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BODの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BODの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BODの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BODの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BODの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/02/20 02:40終値2023/11/23 00:00収益2023/06/30年間収益2023/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bod Science Limited これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Alexander SmithPAC Partners Securities Pty. Ltd.
お知らせ • Aug 25Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022Bod Australia Limited provided revenue guidance for the fiscal year 2022. The Company expects that revenue will continue to increase during FY2022, driven by recurring sales orders for CBD wellness products, an ongoing upward trajectory in medicinal cannabis sales, range expansions across both operating divisions and international expansion opportunities.
お知らせ • Nov 10Bod Science Limited announced that it expects to receive AUD 2.05 million in fundingBod Science Limited announced a private placement of 68,333,333 fully paid ordinary shares at an issue price of AUD 0.03 per share for the gross proceeds of AUD 2,049,999.99 on November 8, 2023. The company will raise the funding in two tranches. The company will issue of 26,600,000 shares for the gross proceeds of AUD 80,000 in the first tranche and 41,700,000 shares for the gross proceeds of AUD 1,250,000 in second tranche. Tranche 2 includes the proposed issue of AUD 30,000 worth of shares to Jo Patterson subject to shareholder approval. Assuming Tranche 2 is approved, the transaction will involve the issue of 68.3 million shares. The transaction will include participation from new investor Antah Healthcare Group through a commitment of AUD 1,100,000 worth of shares. On completion of the transaction, it is expected that Antah Healthcare Group will hold a relevant interest of 14.9% of company's issued shares.
お知らせ • Nov 09Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,600,773 Price\Range: AUD 0.03 Security Name: Shares Security Type: Common Stock Securities Offered: 41,732,556 Price\Range: AUD 0.03 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 07Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 19,751,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,875,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 02Bod Science Limited, Annual General Meeting, Nov 27, 2023Bod Science Limited, Annual General Meeting, Nov 27, 2023. Agenda: To consider and approve the re-election of Directors.
Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)Full year 2023 results: AU$0.056 loss per share (further deteriorated from AU$0.051 loss in FY 2022). Revenue: AU$3.64m (down 28% from FY 2022). Net loss: AU$7.95m (loss widened 47% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.
New Risk • Aug 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (AU$14.0m market cap, or US$9.00m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$4.1m revenue, or US$2.6m).
New Risk • Aug 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Market cap is less than US$10m (AU$12.8m market cap, or US$8.31m). Minor Risk Revenue is less than US$5m (AU$4.1m revenue, or US$2.7m).
お知らせ • Aug 11Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.Bod Australia Limited (ASX:BOD) entered into binding agreement to acquire Aqua Phase Ltd for £3 million on August 30, 2022. Bod will pay total consideration of £3 million with Initial payment of £1 million in cash to be paid upon satisfaction of conditions precedent relating to successful completion of upcoming manufacture, stability and bioavailability testing. Remaining consideration paid against further milestone achievements relating to pharmaceutical GMP manufacture and commercialization, with optionality for Bod to pay in cash or shares over a 12-36 month timeframe. The earnout payments are conditional upon ASX and shareholder's approval. As on March 7, 2023, Bod has successfully completed the stability testing of the Aqua Phase product format within the agreed time frame, along with the manufacture of a technical batch per the acquisition terms and timeframe. Due to third party delays involved in the testing and analyzing phase of the PK study, Bod Science has agreed with the Inventors to extend the date by which this test must be completed to June 30, 2023. As on March 28, 2023, Bod Science is pleased to report the PK study to confirm the bioavailability of Aqua Phase has been submitted for ethics approval, with approval expected within 2 weeks. Recruitment for study participants will commence immediately once ethics approval is received. The PK study will recruit 12 subjects and will continue for 4 weeks. Results are expected in June 2023. Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd on August 10, 2023.
Reported Earnings • Feb 25First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)First half 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.02 loss in 1H 2022). Revenue: AU$2.57m (down 25% from 1H 2022). Net loss: AU$3.17m (loss widened 46% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
お知らせ • Jan 24Bod Science Limited Announces Company Secretary ChangesBod Science Limited announced the appointment of Carlie Hodges as Company Secretary upon the resignation of Stephen Kelly, effective 23 January 2023. Carlie is a practising corporate and commercial lawyer, holds a Graduate Diploma in Applied Corporate Governance and is a Fellow Member of the Governance Institute of Australia.
お知らせ • Nov 22Bod Australia Limited Provides Statistical Summary from Its Phase 1 Cannabidiol (CBD) Pharmacokinetic (PK) StudyBod Australia Limited provide the following statistical summary from its Phase 1 cannabidiol (CBD) pharmacokinetic (PK) study. The PK study, undertaken as part of a number of elements within Bod's Schedule 3 (pharmacist only) project, forms a critical and required step for the Company's dossier submission to the TGA (Therapeutic Goods Association). Bod's ongoing Phase IIb clinical trial underpins the Company's drive to develop a new Schedule 3 (pharmacist only) CBD product to be made available to the Australian market. This supports Bod's strategy of consistently selling products through SAS-B channels since 2018 which has allowed the Company to build a strong foothold in the market. The PK study consisted of 3 oral treatment arms delivered as a single dose in a crossover design in 14 healthy subjects between 18-50 years old, each equating to 100mg CBD per day: Bod ECS BioAbsorb Soft Gel Capsule; Epidyolex Oil (a TGA & FDA-approved, plant-derived, purified prescription cannabidiol); CBD isolate in MCT oil (a supplement made from a structure of fat termed medium-chain triglycerides). Statistical analysis received on the study supports the potential for Bod's unique ECS BioAbsorb Soft Gel to be the benchmark delivery format for the over the counter CBD market. The below outcomes were reported in relation to the trial's primary and secondary endpoints: Bod ECS BioAbsorb Softgel showed over 20% greater concentration of CBD in the blood than Epidyolex; Bod ECS BioAbsorb Softgel showed over 400% greater concentration of CBD in the blood than CBD Isolate Oil solution; The maximum concentration of CBD after a single oral administration of Bod ECS BioAbsorb Softgel was over 60% greater than Epidyolex; The maximum concentration of CBD after a single oral administration of Bod ECS BioAbsorb Softgel was 600% more than CBD Oil solution; The time to reach the maximum concentration of CBD after single oral administration of Bod ECS BioAbsorb Softgel was twice as fast as Epidyolex and five times faster than CBD Oil solution.
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 09Bod Australia Limited Announces Resignation of Hanno Cappon as Non-Executive DirectorBod Australia Limited advised that Mr. Hanno Cappon has resigned as Non-Executive Director with immediate effect. Mr. Cappon joined the Company's Board in July 2021 as one of two Directors appointed by NewH2 and H&H pursuant to the investment agreement between the Company and NewH2 and H&H. Following the completion of the recent placement and entitlement offer, NewH2's shareholding in the Company has reduced to less than ten per cent of the Company's fully paid ordinary shares on issue and, in accordance with the investment agreement, the number of Directors appointed by NewH2 and H&H is to be reduced to a single Director. Mr. Akash Bedi will remain on the Board as the appointee of NewH2 and H&H. The Company continues to assess additional director candidates to ensure it has adequate diversity and the necessary skill sets to advance its current clinical trial pipeline and product commercialisation initiatives. The Company advises that following Mr. Cappon's resignation, Resolution 15 from the agenda of the Annual General Meeting of Shareholders scheduled for 4.00pm (AEDT) on 28 November 2022 has been withdrawn.
お知らせ • Oct 18Bod Australia Limited, Annual General Meeting, Nov 28, 2022Bod Australia Limited, Annual General Meeting, Nov 28, 2022.
Reported Earnings • Aug 31Full year 2022 earnings released: AU$0.051 loss per share (vs AU$0.043 loss in FY 2021)Full year 2022 results: AU$0.051 loss per share (down from AU$0.043 loss in FY 2021). Revenue: AU$5.28m (down 29% from FY 2021). Net loss: AU$5.41m (loss widened 28% from FY 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.
お知らせ • Jun 23Bod Australia Limited to Launch a New Medicinal Cannabis Product to the Australian Market in JulyBod Australia Limited announced that it will launch a new medicinal cannabis product to the Australian market in July, available to consumers through the Therapeutic Goods Administration's (TGA) Special Access Scheme Category B.The TGA's Schedule Access Scheme allows certain healthcare practitioners to access certain therapeutic goods including medicines, medical devices and biologicals that are not included in the Australian Register of TherapeuticGoods (ARTG) for a single patient. Bod has been consistently selling products through SAS-B channels since 2018 and has built a strong foothold in the market. The new product will be launched under Bod's existing medicinal cannabis brand as MediCabilisTM and sold as Bod Bio-Absorb 100TM. Bio-Absorb 100TM is made up of a uniquely developed CBD formulation in a soft gel delivery format and is currently being utilised in the Company's phase II clinical trial. The launch will highlight the Company's fourth product available to Australian consumers through prescription channels. Upon successful completion of Bod's phase II clinical trial and other required regulatory approvals, Bio-Absorb 100TM will be sold over-the-counter through pharmacists. The launch of Bod Bio-Absorb 100TM will expand Bod's existing medicinal cannabis range, introduce a new delivery format for consumers and complement the Company's existing products that are being used to alleviate a range of conditions including chronic pain, anxiety and insomnia amongst others. To drive product awareness and uptake, the Company has engaged with a number of healthcare professionals and approved prescribers to further educate them on the benefits of Bod Bio-Absorb 100TM. Bod will provide additional updates on the launch and product sales growth as it materialises.
お知らせ • May 26Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising ResultsBod Australia Limited announced that it has completed a proof of concept study into the safety and efficacy of a cannabigerol (CBG) dominant cannabis extract which has shown very promising results. The study will form the basis for the launch of a new medicinal cannabis product that will be sold under Bod's existing medicinal cannabis brand as MediCabilisTM CBG 50, expected to launch in June 2022. CBG is a non-intoxicating cannabinoid compound, found in the cannabis plant. It holds strong therapeutic potential across a range of applications. Preliminary research has indicated that CBG has unique pharmacological actions and has the potential to address alternative therapeutic areas to THC and CBD. The extract has been shown to be beneficial in the treatment of fibromyalgia, inflammatory bowel disease and irritable bowel syndrome (IBS) amongst others. Treatment of these conditions commonly includes a mix medication, surgery and self-care strategies, with no single treatment procedure working on all symptomsi. Bod's proof of concept study was conducted over a three month period to assess the safety and efficacy of MediCabilisTM CBG 50 in patients suffering from symptoms associated with fibromyalgia, inflammatory bowel disease and anxiety. During the trial, participants were administered 50mg/ml of the product orally, twice daily and asked to rate the improvement in symptoms on a scale of one to ten, with one being nothing to ten being the best improvement. A comprehensive review of the data highlighted that 74% of trial participants reported a noticeable improvement in their conditions within two to four weeks of using MediCabilisTM CBG 50 twice a day. When participants were asked to rate the improvement on a scale of one to ten, 64% reported a rating above six. The detailed trial data will be shared with doctors and approved prescribers in both Australia and the UK to assist in the ongoing educational initiatives undertaken by the Company and to support the launch of MediCabilisTM CBG 50. The Company expects to launch MediCabilisTM CBG 50 in June 2022 via prescription channels. This will complement and expand Bod's existing medicinal cannabis product range, which is currently being used to alleviate a range of conditions including chronic pain, anxiety and insomnia amongst others. Bod will also become the first company to launch a pharmaceutical grade CBG product in the Australian and UK prescription market, providing another channel to grow medicinal cannabis sales.
お知らせ • May 18Bod Australia Limited Announces Board ChangesBod Australia Limited advised that Mr. Mark Masterson has resigned as Non-Executive Chairman, effective from May 16, 2022 due to personal reasons. Recently appointed Non-Executive Director Mr. David Baker will now assume the role of Non-Executive Chairman. Mr. Baker joined the Company in April 2022. He is a commercial adviser and company director with over 40 years' experience in law, investment banking, public company leadership and corporate governance. Mr. Baker is also a longstanding shareholder in Bod.
お知らせ • May 12Bod Australia Limited Advises That It Has Successfully Enrolled First Patients for Its Australian-Based Planned Phase Iib Clinical TrialBod Australia Limited advised that it has successfully enrolled first patients for its Australian-based planned Phase IIB clinical trial to investigate the efficacy of a new, unique Schedule 3(pharmacist only) CBD formulation on symptoms associated with insomnia. Bod's trial is a double blind, randomised and placebo-controlled investigation of the effect of administering a 50mgand 100mg oral CBD product per day, versus a placebo, over an 8-week period with over 200 participants. Upon completion of the study, Bod is confident that it will have sufficient data to progress product registration for Schedule 3 low dose CBD product with the Therapeutic Goods Administration (TGA) and for the final product to be added to the Australian Register of Therapeutic Goods (ARTG). Expected to be one of the first companies in Australia to do so, the completion of this process provides Bod with a unique CBD product that can be sold over-the-counter by a pharmacist to Australian consumers who are seeking to alleviate symptoms of insomnia, without the requirement of a prescription. With a potential market valued at$250m, the new product will unlock another channel for Bod to significantly increase domestic sales. Importantly, the clinical trial has the potential to unlock opportunities in the growing global insomnia market, which is expected to reach USD 6.38Bn in value by 2030.
お知らせ • Apr 27Bod Australia Limited Announces First Patients Enrolled for Long-Covid Study Investigating the Efficacy of CBD- Dominant Medicinal CannabisBod Australia Limited announced that it has enrolled first patients for its UK-based open label clinical trial in collaboration with Drug Science UK to explore the effectiveness of Bod's medicinal cannabis product MediCabilis® CBD 5% (`MediCabilis') on associated with the long term impact of SARS-CoV-2 (`COVID-19'), which is commonly referred to as long-COVID. Long-COVID is an emerging condition referring to the ongoing or new symptoms that develop in the eight weeks following an initial COVID-19 infection. The condition may include the continuation of COVID-19 symptoms frominitial diagnosis, or new symptoms that arise around a month after contracting the disease. Symptoms of long-COVID include shortness of breath, fatigue, ongoing chest discomfort, loss of concentration, chronic pain, anxiety and insomnia. Many of these are amenable to treatment with cannabis-based medicines, highlighting Bod's significant near-term opportunity. The study aims to recruit 30 participants over the age of 18 that are suffering from long-COVID. Under a clinical trial setting, each patient will be administered MediCabilis on a daily basis over a six month period and undertake self- reporting assessing common long-COVID symptoms including breathlessness, fatigue, cognition and pain through a dedicated smartphone application. The collective results of the trial will determine the feasibility of Bod's medicinal cannabis product in the treatment of the condition and whether it is effective and safe to use for long COVID condition. The results from the clinical trial will allow Bod to continue the potential commercialization of a product which can alleviate symptoms of long-COVID, provide the Company with additional evidence in the use of MediCabilisand assist Bod in progressing potential Licensing agreements with large pharmaceutical partners or other corporates for its unique extract.
Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Chairman Mark Masterson was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 04Bod Australia Announces Board ChangesBod Australia Limited advised that Mr. Simon O'Loughlin has retired as a Non-Executive Director. Mr. O'Loughlin will be replaced by Mr. David Baker. Mr. Baker has been appointed as a Non-Executive Director effective 4 April 2022. Mr. Baker is a commercial advisor and company director with over 40 years' experience in law, investment banking, public company leadership and corporate governance. He has deep industry knowledge across a range of sectorsand a sophisticated understanding of financial markets.
Reported Earnings • Feb 28First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.02 loss per share (down from AU$0.014 loss in 1H 2021). Revenue: AU$3.44m (up 4.0% from 1H 2021). Net loss: AU$2.17m (loss widened 68% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
お知らせ • Feb 21Bod Australia Limited's Novel Food Application Accepted by UK Food Service AgencyBod Australia Limited to advise that its submitted dossier to the United Kingdom's Food Service Agency to register its exclusive cannabis extract as a novel food in the UK has been validated - the final step in this process will be to receive the registration. The Company's dossier is currently under review by the regulator and final approval is expected in the coming months. Lodgement of the dossier follows changes by the FSA that required products containing CBD be subject to novel food standards. The deadline for submissions was March 2021, and approval will allow Bod's range of CBD products to continue to be sold in the UK legally. It will also provide the Company with the opportunity to pursue additional partnerships to introduce new products across a range of verticals. Bod has an established footprint in the UK and currently distributes both medicinal cannabis and CBD wellness products in the region. Bod's leading MediCabilis Medical Cannabis product is available through the special access market via prescription. Bod also sells 15 CBD wellness products through its, global partner, Health & Happiness Group Limited under brands CBII and Swisse. The pending approval reinforces the quality of the Company's CBD extract and provides Bod with a significant competitive advantage. It will also allow the Company to progress the introduction of new CBD-based, over the counter products in other high growth verticals including skincare, beverages and lifestyle products, functional food and pet treats. The Company is in discussions with a number of potential partners and will provide additional updates as developments materialise. Bod has undertaken a considerable amount of work to progress the registration with the FSA, including toxicology studies, stability testing and extract analysis initiatives. The data from these studies has also been used to advance European novel foods registration through EFSA. European novel foods registration is expected to unlock several additional opportunities, allowing Bod to broaden its global footprint.
お知らせ • Jan 24Bod Australia Limited Announces Ethics Approval Received for Schedule 3 Clinical TrialBod Australia Limited advised that the company's planned phase IIB clinical trial to be undertaken at the Woolcock Institute of Medical Research has received ethics approval from Bellberry Limited. The trial will investigate the efficacy of a new unique Schedule 3 (pharmacist only) CBD formulation on symptoms associated with insomnia. This is a major milestone for the Company allowing the immediate commencement of participant recruitment for the study. The Woolcock Institute of Medical Research is Australia's leading sleep and respiratory research organisation. The trial will be a double blind, randomised and placebo-controlled investigation of the effect of administering a 50mg and 100mg oral CBD product per day, versus a placebo, over a 8-week period with over 200 participants. The clinical trial is one of the first registered in Australia for a Schedule 3 CBD product. Following completion of the study, Bod expects to have sufficient data to commence product registration for a Schedule 3 low dose CBD product with the Therapeutic Goods Administration (TGA) and for the product to be included on the Australian Register of Therapeutic Goods (ARTG). It is anticipated that completion of this process will provide Bod with a low dose CBD product that can be sold over-the-counter by a pharmacist to Australian consumers without a prescription. This unlocks another channel to market for the Company and has the potential to significantly increase domestic sales, underpinning additional revenue growth. Insomnia provides a large opportunity for Bod. In an estimated global market of $5.4 Billion by 2023, current pharmacological interventions for the treatment of insomnia have major limitations including abuse and dependence, questionable or uncertain efficacy and hangover effects. The successful development of Bod's product will provide it with a defined pathway to market and an opportunity to grow its market share. Ethics approval underpins Bod's strong momentum bringing its Schedule 3 products to market. Participant recruitment will commence shortly and Bod is also in advanced discussions with a number of potential partners for its Schedule 3 CBD products and expects to provide additional updates on these over the coming months.
お知らせ • Jan 18Bod Australia Limited Announces Secures Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory AgencyBod Australia Limited announced that it has secured Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory Agency ("MHRA") to commence an open label clinical trial in association with Drug Science UK to explore the effectiveness of Bod's medicinal cannabis product, MediCabilis® 5% ("MediCabilis®") on symptoms associated with the long term impact of SARS-CoV-2 ("COVID-19"), commonly referred to as long-COVID. This initiative provides Bod with an important opportunity to build on the growing body of evidence for the use of MediCabilis®, as well as insight into the potential use of the product as a treatment against long-COVID. Upon completion of the trial and pending successful results, Bod will embark on the commercialisation of a MediCabilis® product which can be used to treat the condition. The Company anticipates that this will lead to increased sales volumes across the UK and other territories. Long-COVID is an emerging condition referring to persistent or new symptoms that develop at least eight weeks following an initial COVID-19 infection. Long-COVID may include the continuation of symptoms from when an individual is first infected, or new symptoms where individuals feel they have improved and a month after being infected symptoms arise again. Under the clinical trial setting, recruits will be administered Bod's medicinal cannabis product, MediCabilis®,on a daily basis, over a six-month period. Each participant will undertake monthly and daily self-reporting assessing common long-COVID symptoms such as breathlessness, fatigue, cognition and pain via a smartphone app. The collective results will determine the feasibility of medicinal cannabis and MediCabilis® in the treatment of the condition and whether it is safe to use.
分析記事 • Sep 23Here's Why We're Watching Bod Australia's (ASX:BDA) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
お知らせ • Aug 25Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022Bod Australia Limited provided revenue guidance for the fiscal year 2022. The Company expects that revenue will continue to increase during FY2022, driven by recurring sales orders for CBD wellness products, an ongoing upward trajectory in medicinal cannabis sales, range expansions across both operating divisions and international expansion opportunities.
Reported Earnings • Aug 24Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$7.53m (up 27% from FY 2020). Net loss: AU$4.23m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
お知らせ • Jun 17Bod Australia Limited Launches New CBD -Based ProductsBod Australia Limited announced that it has broadened its sales footprint in the United Kingdom via two new online retailers, following the launch of new CBD-based products sold under the CBII brand. The CBII range will now be stocked with Europe's number one online premium health and beauty retailer Lookfantastic, as well as Feelunique, one of Europe's leading premium ecommerce beauty retailers. Lookfantastic is one of the most successful beauty websites globally, stocking 660 premium brands and shipping to over 200 countries. Its UK website generates over 10 million visits per month. The group has grown revenue share 40% year on year for the last three yearsii and is underpinned by unrivalled technology, supply chain management and a team of world-class experts in the beauty and healthcare space. Initially, Lookfantastic will focus on the sale and distribution of CBII products in the UK, with both parties exploring the potential to expand availability to other countries where CBD is legally permissible for sale. CBII products will be launched on Lookfantastic's website in the coming weeks.
分析記事 • Jun 07Bod Australia (ASX:BDA) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • May 18Bod Australia Limited Provides Update on New Medicinal Cannabis Product LaunchBod Australia Limited provided the update on a new medicinal cannabis product launch and recent MediCabilisTM prescription growth in the United Kingdom. The Company is launching a new cannabigerol (CBG) product, which will be sold under the MediCabilis brand as MediCabilisTM CBG 50 in the United Kingdom. CBG is a non-intoxicating cannabinoid compound in the cannabis plant, which holds strong therapeutic potential for use in broad therapeutic applications. Preliminary research indicates that CBG has unique pharmacological actions and has the potential to address alternative therapeutic areas to THC and CBD. CBG has a different chemical structure to CBD and THC and will bind onto specific cell receptors for different therapeutic targets. Bod is launching the product following R&D assessments, with the introduction as part of the Company's approach to developing specific cannabis cultivators and product formats for current and future new product development. The market for CBG is in its early stages and is expected to grow significantly in the coming years. The launch of MediCabilisTM CBG 50 will provide Bod with a first-mover advantage and leaves the Company very well placed to capitalise. Initially, Bod will focus on launching the product in the UK, through select doctors and healthcare physicians. The introduction of MediCabilisTM CBG 50 is expected to support incremental market growth across the region, as well and provide additional R&D and clinical research opportunities. Bod reported strong quarter on quarter MediCabilisTM prescription growth in the UK. During previous quarter, the Company filled a total of 59 MediCabilisTM units, which marks a 90% increase on the previous quarter. Bod expects that UK MediCabilisTM prescription volumes will continue an upward trajectory following the launch of the Company's new CBG product, Project Twenty21 scale up and ongoing educational initiatives to promote the company's products with approved prescribers in the UK market.
Executive Departure • Apr 02Chief Financial Officer has left the companyOn the 29th of March, Charles Altshuler's tenure as Chief Financial Officer ended after 2.2 years in the role. We don't have any record of a personal shareholding under Charles' name. Charles is the only executive to leave the company over the last 12 months.
分析記事 • Feb 22Why Bod Australia's (ASX:BDA) CEO Pay MattersThe CEO of Bod Australia Limited ( ASX:BDA ) is Jo Patterson, and this article examines the executive's compensation...
お知らせ • Feb 19Bod Australia Limited Announces the Resignation of Charles Altshuler as Chief Financial Officer, Effective 31 March 2021Bod Australia Limited announced that Charles Altshuler has resigned from his position as Chief Financial Officer, effective 31 March 2021. Charles was appointed to the position in February 2019 and has assisted Bod in achieving a number of critical milestones. The Board of Bod Australia Limited wish him well for his future endeavours. The company will provide a further announcement upon the appointment of a new Chief Financial Officer when applicable.
Is New 90 Day High Low • Feb 01New 90-day low: AU$0.42The company is down 14% from its price of AU$0.49 on 03 November 2020. The Australian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 1.0% over the same period.
お知らせ • Dec 13Bod Australia Limited announced that it expects to receive AUD 8 million in fundingBod Australia Limited (ASX:BDA) announced a private placement of 14,545,455 common shares at a price of AUD 0.55 per share for gross proceeds of AUD 8,000,000.25 on December 11, 2020. The transaction will include participation from from institutional and sophisticated investors. The company expects to close the transaction on December 21, 2020.
お知らせ • Dec 03Bod Australia Limited Receives AUD 200,000 Binding Purchase Order from Exclusive Global PartnerBod Australia Limited announced that it has received a AUD 200,000 binding purchase order from exclusive global partner, Health & Happiness Group Limited for four Swisse Wellness ('wisse') branded hemp seed oil products. The products will be sold in France, as well as through existing channels in the Netherlands and the United Kingdom, considerably broadening Bod's product offering in Europe. The products will be sold in soft gel cap form and designed to target specific need states including sleep, energy levels, stress and general wellness. The development marks Bod's entry into the French market. Bod and H&H will launch the products directly to consumers in France through Swisse's established ecommerce channels. Distribution to retail outlets is earmarked for future development. H&H will initiate marketing campaigns to progress product uptake and awareness in the country, as well as manage distribution. The new hemp seed oil products will also be sold through online channels in the United Kingdom, the Netherlands and Italy. Bod will receive a royalty on net product sales, as well as a cost plus margin for the supply of its extracts and formulas, unlocking more revenue streams. The binding purchase order follows a decision from the Court of Justice of the European Union ("CJEU") on 19 November 2020 which ruled that member states cannot prohibit the marketing of lawfully produced CBD. The CJEU ruled that CBD is not considered a narcotic and as a result, can be freely sold in the European Unionii.
Is New 90 Day High Low • Nov 24New 90-day high: AU$0.61The company is up 110% from its price of AU$0.29 on 26 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 6.0% over the same period.
お知らせ • Nov 18Bod Australia Limited Announces Strong Growth in Medicinal Cannabis Sales ContinuesBod Australia Limited announced that it has continued its strong medicinal cannabis sales growth filling 755 MediCabilis(TM) prescriptions during October 2020. This outlines a 106% increase on the average monthly prescription volumes since July 2019 (average monthly volumes: 371). October prescription volumes were part of the record purchase order received during first quarter of 2021 for 2,630 units, which following delivery, will now be booked as sales. Bod has now filled a total of 4,400 prescriptions since January 2020, which marks a 124% increase on 2019 volumes (2019 total prescription volumes: 1,959). The ongoing upward trajectory in prescription volumes has significantly added to the Company's revenue profile and demonstrates the traction that MediCabilis(TM) is gaining in the Australian market with a wide range of new and repeat patients. Repeat prescriptions for October accounted for 60% of the month's total volume. This highlights patient and physician satisfaction with the product, as well as the benefits MediCabilis(TM) is delivering to patients by alleviating chronic conditions. MediCabilis(TM) is being prescribed for a range of conditions and Bod now has a 57% market share in the addressable market defined by full plant, high CBD products in Australia. This is a major achievement given the highly competitive nature of the market. Bod anticipates that strong MediCabilis(TM) sales growth will continue over the coming months in Australia due to the increased brand recognition being achieved, and the Company's nationwide clinical observational study.
お知らせ • Oct 20Bod Australia Limited Launches CBD Products in the NetherlandsBod Australia Limited advised that it has launched four new CBD products in the Netherlands, under recognised Australian vitamin and skincare brand Swisse Wellness ("Swisse"). The CBD products, which are in soft gel cap form and designed to target specific need states including immune function and joint mobility, are now being sold through Swisse's ecommerce channels and in store at established health food chain Holland and Barrett. A Swisse-branded marketing and sales campaign and in store promotions are supporting the launch. The launch follows Bod's exclusive global partnership with Swisse's parent company, Health and Happiness Group Limited and marks the third major market into which both parties have successfully launched products. Bod and H&H's products are now being sold in Australia, the United Kingdom and the Netherlands, with entry into additional European countries and the United States expected in coming months. As per the Company's exclusive licensing agreement with H&H, Bod will receive a royalty on net product sales as well as a cost plus margin for the supply of its CBD extract and formulas. Revenue from first Netherland sales is expected to fall in the current quarter as products are now available to consumers.
お知らせ • Oct 15Bod Australia Limited Undertakes a Phase I Trial of the Safety Tolerability and Pharmacokinetics of Cannabidiol, Administered in Healthy Volunteers Across Multiple FormulationsBod Australia Limited has undertaken a Phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol (CBD), administered in healthy volunteers across multiple formulations, conducted at the Nucleus Network. The study, published in leading British Journal of Clinical Pharmacology, demonstrates the safety, tolerability and bioavailability of Cannabis sativa – Linnea 315CSE extract (available as MediCabilis(TM) Cannabis sativa 50) in oil and sublingual wafer formation compared to nabiximols oromucosal spray. About 43% of the adults in the UK have chronic pain, with as many as 14.3% having moderate to severely disabling chronic pain. Chronic pain is highly resistant to existing pharmaceutical treatment.
Is New 90 Day High Low • Oct 15New 90-day high: AU$0.53The company is up 104% from its price of AU$0.26 on 17 July 2020. The Australian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 41% over the same period.
Is New 90 Day High Low • Sep 28New 90-day high: AU$0.40The company is up 46% from its price of AU$0.27 on 30 June 2020. The Australian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 16% over the same period.